Ruey-ching (Richard) Hwang, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruey-ching (Richard) Hwang, PhD


Ruey-ching (Richard) Hwang, PhD
Senior Director,
Pharmaceutical Sciences
Pfizer Global R&D

Richard (Ruey-ching) Hwang is senior director of clinical supply manufacturing at Pfizer and has been with the company since 2003. He previously held positions at Pharmacia, Mallinckrodt, and G.D. Searle.

Hwang has authored and/or coauthored nearly 20 papers, given nearly 40 presentations and training courses, and presented more than 20 posters at poster sessions. He is a member of the American Association of Pharmaceutical Scientists (AAPS) and is a member of Pharmaceutical Technology’s Editorial Advisory Board.

He holds an MBA from the Keller Graduate School of Management at DeVry University and a PhD in Pharmaceutics from the College of Pharmacy at the University of Iowa. He received his BS in Pharmacy from the School of Pharmacy, College of Medicine, National Taiwan University.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here